Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
UNIVERSITA AUTÒNOMA DE BARCELONA has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners and 3 distinct art units, indicating separate examination assignments.
LOUNTOS, GEORGE THEMISTOCLIS is the busiest examiner, with 1 pending matter. Counsel should preserve consistent portfolio positions while tailoring responses to each examiner and unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LOUNTOS, GEORGE THEMISTOCLIS | 1 | 57.1% | +60.0% |
| NICOL, ALEXANDER W | 1 | 42.7% | +43.6% |
| POPA, ILEANA | 1 | 21.7% | +15.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17189368 | TELOMERASE REVERSE TRANSCRIPTASE-BASED THERAPIES | POPA, ILEANA | 22d |
| 19104240 | Beta-hexosaminidase vectors | LOUNTOS, GEORGE THEMISTOCLIS | — |
| 17614390 | Insulin gene therapy | NICOL, ALEXANDER W | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17189368 | TELOMERASE REVERSE TRANSCRIPTASE-BASED THERAPIES | POPA, ILEANA | 22d |
| 19104240 | Beta-hexosaminidase vectors | LOUNTOS, GEORGE THEMISTOCLIS | — |
| 17614390 | Insulin gene therapy | NICOL, ALEXANDER W | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| 1634 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19104240 | Beta-hexosaminidase vectors | LOUNTOS, GEORGE THEMISTOCLIS | 1652 | §102§103§112 | Non-Final OA | — | Pending | Feb 17, 2025 |
| 17614390 | Insulin gene therapy | NICOL, ALEXANDER W | 1634 | §103§112 | Non-Final OA | — | Pending | Nov 26, 2021 |
| 17189368 | TELOMERASE REVERSE TRANSCRIPTASE-BASED THERAPIES | POPA, ILEANA | 1633 | §103 | Final Rejection | 22d | Pending | Mar 02, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITA AUTÒNOMA DE BARCELONA has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
George Themistoclis Lountos has the most, with 1 of UNIVERSITA AUTÒNOMA DE BARCELONA's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
